Alcoholic Hepatitis Study

Clinical Trial Title

A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of an investigational drug in Subjects with Alcoholic Hepatitis

National Clinical Trial Number:

NCT04563026

Contact Information

Clinical Trial Protocol Description:

This study aims to evaluate the safety and efficacy of an investigational drug compared to placebo in subjects with Alcoholic Hepatitis. Subjects enrolled in the study must be admitted to a RUSH inpatient hospital floor. This study involves outpatient clinic visits following discharge from the hospital.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have Maddrey discriminant function (MDF) greater than or equal to 32.
  • Have Model for End-stage Liver Disease (MELD) score: 21-30.
  • Have not taken systemic corticosteroids for a duration exceeding 8 days in the 30 days prior to screening.
  • Do not an active infection.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Costica Aloman

Contact Information

Diana Goldman

Clinical Trial Location

Rush University Medical Center

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more